Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU

被引：0
|
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Adis,
来源：
Drugs & Therapy Perspectives | 2012年 / 28卷 / 12期
关键词：
Multiple Sclerosis; Placebo Recipient; Expand Disability Status Scale; Primary Efficacy Variable; Potassium Channel Blocker;
D O I：
10.1007/BF03262139
中图分类号：
学科分类号：
摘要：
Prolonged-release (PR) fampridine (Fampyra®), a potassium channel blocker, is the first agent to be specifically indicated for the improvement of walking in patients with multiple sclerosis (MS). In clinical trials in patients with MS with impaired walking, PR fampridine 10 mg twice daily improved walking ability to a significantly greater extent than placebo, with improvements being maintained with long-term therapy. PR fampridine 10 mg twice daily is generally well tolerated.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 50 条
  • [1] Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)
    Preiningerova, Jana Lizrova
    Baumhackl, Ulf
    Csepany, Tunde
    Czaplinski, Adam
    Deisenhammer, Florian
    Derfuss, Tobias
    Fabjan, Tanja H.
    Fazekas, Franz
    Fuchs, Siegrid
    Havrdova, Eva
    Ledinek, Alenka Horvath
    Illes, Zsolt
    Jazbec, Sasa Sega
    Klimova, Eleonora
    Komoly, Samuel
    Kurca, Egon
    Linnebank, Michael
    Lisy, Lubomir
    Mares, Jan
    Prochazkova, Lubica
    Csilla, Rozsa
    Szilasiova, Jarmila
    Stourac, Pavel
    Talab, Radomir
    Turcani, Peter
    Vachova, Marta
    Vecsei, Laszlo
    Vodusek, David
    Zapletalova, Olga
    Berger, Thomas
    CNS NEUROSCIENCE & THERAPEUTICS, 2013, 19 (05) : 302 - 306
  • [2] Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
    Fernandez, Oscar
    Berger, Thomas
    Hartung, Hans-Peter
    Putzki, Norman
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (06) : 649 - 665
  • [3] A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis
    Ramio-Torrenta, L.
    Alvarez-Cermeno, J. C.
    Arroyo, R.
    Casanova-Estruch, B.
    Fernandez, O.
    Garcia-Merino, J. A.
    Hernandez, M. A.
    Izquierdo, G.
    Martinez-Yelamos, S.
    Meca, J.
    Moral, E.
    Olascoaga, J.
    Prieto, J. M.
    Saiz, A.
    NEUROLOGIA, 2018, 33 (05): : 327 - 337
  • [4] Effects of prolonged-release fampridine on postural control in patients with multiple sclerosis
    Reuter, K.
    Koeszeghi, L.
    Weller, D.
    Sutter, T.
    Kapitza, S.
    Farkas, M.
    Filli, L.
    Linnebank, M.
    Zoerner, B.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 521 - 521
  • [5] Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis
    Mathiesen, Henrik K.
    Sorensen, Per S.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 1309 - 1317
  • [6] Relationship between Heat Intolerance and Response to Prolonged-Release Fampridine in Patients with Multiple Sclerosis
    Ziemssen, Tjalf
    Berger, Thomas
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [7] Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
    Zoerner, Bjoern
    Filli, Linard
    Reuter, Katja
    Kapitza, Sandra
    Loerincz, Lilla
    Sutter, Tabea
    Weller, David
    Farkas, Melinda
    Easthope, Christopher S.
    Czaplinski, Adam
    Weller, Michael
    Linnebank, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (11) : 1463 - 1475
  • [8] TREATMENT COSTS AND PATTERNS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE IN GERMANY
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    VALUE IN HEALTH, 2015, 18 (07) : A753 - A753
  • [9] Do Cerebellar Symptoms Predict Treatment Response to Prolonged-Release Fampridine in Multiple Sclerosis Patients?
    Siva, Aksel
    Limmroth, Volker
    Potts, James
    Putzki, Norman
    Goodman, Andrew
    NEUROLOGY, 2012, 78
  • [10] Treatment patterns and costs among patients with multiple sclerosis treated with prolonged-release fampridine in Germany
    Lee, A.
    Liu, Y.
    Gleissner, E.
    Prosser, C.
    Kinter, E.
    Landsman-Blumberg, P.
    Braun, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 670 - 670
12345